牛皮关节炎和脊椎关节炎患者的双重向治疗:来自西班牙的现实世界多中心体验
Cristina Valero-Martínez1, Judit Font Urgelles2, Meritxell Sallés3
1Rheumatology Unit, Hospital U. de La Princesa, IIS-Princesa, Madrid, Spain.
Frontiers in immunology
|November 8, 2023
概括
双重向疗法 (DTT) 对耐性脊椎关节炎 (SpA) 和牛皮性关节炎 (PsA) 有望,在许多具有有利安全性概况的患者中实现显著的临床改善和低疾病活性.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 双重向治疗 (DTT) 是一种针对耐火性脊髓关节炎 (SpA) 和牛皮性关节炎 (PsA) 的新策略.
- DTT的有效性和安全性,尤其是肌肉骨外表现,需要进一步的现实研究.
研究的目的:
- 在现实环境中评估DTT的有效性和安全性,用于耐火性SpA和PsA患者.
- 确定常见的DTT组合,并评估它们对疾病活性和葡萄皮质类药物戒断的影响.
主要方法:
- 对36名耐火性SpA或PsA患者进行了双重向药物的回顾性多中心研究.
- 使用化脊柱炎疾病活动评分 (ASDAS-CRP) 和牛皮关节炎疾病活动 (DAPSA) 评估的有效性.
- 对DTT组合,保留率,临床改善和不良事件的分析.
主要成果:
- 确定了39种DTT组合,最常见的是TNF抑制剂加上IL12/23或IL-17对抗剂.
- 在14.86个月的中位数中,观察到69.4%的DTT保留率.
- 显著的临床改善 (69.4%) 和低活性/缓解 (58.3%) 得到了实现; 55%的患者在葡萄糖皮质类药物撤回他们.
- 只有三名患者出现了严重的不良事件,需要停止DTT治疗.
结论:
- 双重向治疗在耐火性SpA和PsA中表现出显著的有效性,包括那些患有炎症性肠病的人.
- 在现实患者群体中,DTT提供了有利的安全概况,并促进了葡萄糖皮质激素的减少.
- 这项研究支持DTT作为一种可行的治疗选择,用于复杂的SpA和PsA病例.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Drugs for Treatment of Ulcerative Colitis in IBD
146
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
146
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
147
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
147


